En reduceret dosis på 250 mg didanosin, der administreres samtidig med tenofovirdisoproxilfumarat, er blevet sat i forbindelse med rapporter om høj forekomst af manglende virologisk effekt i flere testede kombinationer til behandling af HIV- 1- infektion.
A decreased dosage of 250 mg didanosine co-administered with tenofovir disoproxil fumarate therapy has been associated with reports of high rates of virological failure within several tested combinations for the treatment of HIV-1 infection.